Home LiteratureArticle Details
PMID: 19786778 Published · ppublish English Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI).

Dementia and geriatric cognitive disorders ·Vol. 28 ·No. 3 ·2009-00-00 ·Pages 259-66

Haense C, Herholz K, Jagust WJ, Heiss WD

Abstract

We investigated the performance of FDG PET using an automated procedure for discrimination between Alzheimer's disease (AD) and controls, and studied the influence of demographic and technical factors. FDG PET data were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) [102 controls (76.0 +/- 4.9 years) and 89 AD patients (75.7 +/- 7.6 years, MMSE 23.5 +/- 2.1) and the Network for Standardisation of Dementia Diagnosis (NEST-DD) [36 controls (62.2 +/- 5.0 years) and 237 AD patients (70.8 +/- 8.3 years, MMSE 20.9 +/- 4.4). The procedure created t-maps of abnormal voxels. The sum of t-values in predefined areas that are typically affected by AD (AD t-sum) provided a measure of scan abnormality associated with a preset threshold for discrimination between patients and controls. AD patients had much higher AD t-sum scores compared to controls (p < 0.01), which were significantly related to dementia severity (ADNI: r = -0.62, p < 0.01; NEST-DD: r = -0.59, p < 0.01). Early-onset AD patients had significantly higher AD t-sum scores than late-onset AD patients (p < 0.01). Differences between databases were mainly due to different age distributions. The predefined AD t-sum threshold yielded a sensitivity and specificity of 83 and 78% in ADNI and 78 and 94% in NEST-DD, respectively. The automated FDG PET analysis procedure provided good discrimination power, and was most accurate for early-onset AD.

MeSH Terms
Aged Aged, 80 and over Alzheimer Disease/diagnostic imaging Area Under Curve Data Interpretation, Statistical Databases, Factual Female Fluorodeoxyglucose F18 Humans Image Processing, Computer-Assisted Male Middle Aged Positron-Emission Tomography Radiopharmaceuticals Reproducibility of Results
Chemicals
Radiopharmaceuticals Fluorodeoxyglucose F18
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Haense C
Max Planck Institute for Neurological Research, Cologne, Germany.
Herholz K
Jagust W J
Heiss W D
References (36)
36 references, click to expand
  1. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.
    J Nucl Med. 2008 Mar;49(3):390-8 PMID: 18287270
  2. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults.
    Neurology. 1995 Nov;45(11):2077-84 PMID: 7501162
  3. Cortical abnormalities in Alzheimer's disease.
    Ann Neurol. 1984 Dec;16(6):649-54 PMID: 6335378
  4. Severity of vascular dementia is related to volume of metabolically impaired tissue.
    Arch Neurol. 1992 Sep;49(9):909-13 PMID: 1520079
  5. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.
    Ann Neurol. 1997 Jul;42(1):85-94 PMID: 9225689
  6. Age, neuropathology, and dementia.
    N Engl J Med. 2009 May 28;360(22):2302-9 PMID: 19474427
  7. PET studies in dementia.
    Ann Nucl Med. 2003 Apr;17(2):79-89 PMID: 12790355
  8. The role of biomarkers in clinical trials for Alzheimer disease.
    Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):6-15 PMID: 16493230
  9. Fully automatic diagnostic system for early- and late-onset mild Alzheimer's disease using FDG PET and 3D-SSP.
    Eur J Nucl Med Mol Imaging. 2006 May;33(5):575-83 PMID: 16470370
  10. Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease.
    Neuroimage. 2008 May 1;40(4):1503-15 PMID: 18343688
  11. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients.
    Brain. 2005 Aug;128(Pt 8):1790-801 PMID: 15888536
  12. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
    J Psychiatr Res. 1975 Nov;12(3):189-98 PMID: 1202204
  13. Positron emission tomography imaging in dementia.
    Br J Radiol. 2007 Dec;80 Spec No 2:S160-7 PMID: 18445746
  14. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.
    Neuroimage. 2002 Sep;17(1):302-16 PMID: 12482085
  15. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71 PMID: 11526211
  16. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.
    Lancet Neurol. 2007 Aug;6(8):734-46 PMID: 17616482
  17. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease.
    J Neurol Sci. 2002 Aug 15;200(1-2):27-32 PMID: 12127672
  18. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.
    Brain. 2007 Oct;130(Pt 10):2616-35 PMID: 17704526
  19. Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment.
    Mol Imaging Biol. 2002 Jul;4(4):283-93 PMID: 14537119
  20. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?
    Neurology. 2003 Apr 22;60(8):1374-7 PMID: 12707450
  21. (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.
    J Nucl Med. 2007 Jul;48(7):1129-34 PMID: 17574982
  22. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease.
    Arch Neurol. 2005 Nov;62(11):1728-33 PMID: 16286547
  23. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
    J Nucl Med. 2005 Oct;46(10):1625-32 PMID: 16204712
  24. Alzheimer's disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia.
    J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):715-9 PMID: 12754337
  25. Clinical symptoms associated with age at onset in Alzheimer's disease.
    Am J Psychiatry. 1994 Nov;151(11):1646-9 PMID: 7943455
  26. Robustness of multivariate image analysis assessed by resampling techniques and applied to FDG-PET scans of patients with Alzheimer's disease.
    Neuroimage. 2009 Jun;46(2):472-85 PMID: 19385015
  27. FDG PET imaging in patients with pathologically verified dementia.
    J Nucl Med. 2000 Nov;41(11):1920-8 PMID: 11079505
  28. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.
    J Nucl Med. 1995 Jul;36(7):1238-48 PMID: 7790950
  29. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
    JAMA. 2001 Nov 7;286(17):2120-7 PMID: 11694153
  30. Hippocampal hypometabolism predicts cognitive decline from normal aging.
    Neurobiol Aging. 2008 May;29(5):676-92 PMID: 17222480
  31. On the multivariate nature of brain metabolic impairment in Alzheimer's disease.
    Neurobiol Aging. 2009 Feb;30(2):186-97 PMID: 17651869
  32. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.
    Neurology. 2006 Aug 8;67(3):446-52 PMID: 16894106
  33. Greater abnormalities of brain cerebrospinal fluid volumes in younger than in older patients with Alzheimer's disease.
    Arch Neurol. 1993 Apr;50(4):359-73 PMID: 8460957
  34. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
    Neurology. 1984 Jul;34(7):939-44 PMID: 6610841
  35. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.
    Arch Neurol. 1998 Mar;55(3):326-35 PMID: 9520006
  36. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Am J Psychiatry. 2002 May;159(5):738-45 PMID: 11986126
Article Info
Journal
Dementia and geriatric cognitive disorders
Abbr.
Dement Geriatr Cogn Disord
ISSN
1421-9824
Published
2009-00-00
Epub
2009-00-25
Pages
259-66
Language
English
Region
Switzerland
NLM ID
9705200
PMCID
PMC7077083
Subset
IM
Grants
NIA NIH HHS · U19 AG010483 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]